Last updated 12 days ago
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
400 patients around the world
Available in Brazil, United States
EyePoint Pharmaceuticals, Inc.
2Research sites
400Patients around the world
This study is for people with
Macular Degeneration
Age-related Macular Degeneration
Requirements for the patient
From 50 Years
All Gender
Medical requirements
- Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1).For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.
- Subfoveal fibrosis, atrophy, or scarring in the center subfield.BCVA using ETDRS charts less than 20 letters (20/400 Snellen equivalent) in the fellow eye.
Sites
Retina Clinic
Recruiting
Hospital de Olhos Participações SA Assis-SP
Recruiting
StudywAMD
SponsorEyePoint Pharmaceuticals, Inc.
Study typeInterventional
Conditions
Age-related Macular Degeneration
Requirements
From 50 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06683742
